Does prophylaxis with palivizumab reduce hospitalisation rates for respiratory-syncytial-virus-related infection in cystic fibrosis children less than 2 years of age?

J Paediatr Child Health. 2012 Nov;48(11):1033-8. doi: 10.1111/j.1440-1754.2012.02593.x.
No abstract available

Publication types

  • Review

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Antiviral Agents / therapeutic use*
  • Cystic Fibrosis / virology*
  • Hospitalization / statistics & numerical data*
  • Humans
  • Infant
  • Palivizumab
  • Respiratory Syncytial Virus Infections / drug therapy*
  • Respiratory Syncytial Virus Infections / prevention & control

Substances

  • Antibodies, Monoclonal, Humanized
  • Antiviral Agents
  • Palivizumab